These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 2735205

  • 1. Clinical implications of determination of plasma haloperidol levels.
    Santos JL, Cabranes JA, Almoguera I, Ramos JA, Vazquez C, Angeles F.
    Acta Psychiatr Scand; 1989 Apr; 79(4):348-54. PubMed ID: 2735205
    [Abstract] [Full Text] [Related]

  • 2. Haloperidol plasma levels and acute clinical change in schizophrenia.
    Coryell W, Kelly M, Perry PJ, Miller DD.
    J Clin Psychopharmacol; 1990 Dec; 10(6):397-402. PubMed ID: 2286709
    [Abstract] [Full Text] [Related]

  • 3. Serum haloperidol concentration and clinical response in schizophrenia.
    Kirch DG, Bigelow LB, Korpi ER, Wagner RL, Zalcman S, Wyatt RJ.
    Schizophr Bull; 1988 Dec; 14(2):283-9. PubMed ID: 3201181
    [Abstract] [Full Text] [Related]

  • 4. RBC and plasma levels of haloperidol and clinical response in schizophrenia.
    Smith RC, Vroulis G, Shvartsburd A, Allen R, Lewis N, Schoolar JC, Chojnacki M, Johnson R.
    Am J Psychiatry; 1982 Aug; 139(8):1054-6. PubMed ID: 7091432
    [Abstract] [Full Text] [Related]

  • 5. Clinical response and plasma haloperidol levels in chronic and subchronic schizophrenia.
    Santos JL, Cabranes JA, Vazquez C, Fuentenebro F, Almoguera I, Ramos JA.
    Biol Psychiatry; 1989 Aug; 26(4):381-8. PubMed ID: 2669981
    [Abstract] [Full Text] [Related]

  • 6. Determination of plasma haloperidol concentrations by radioreceptor assay in schizophrenia: clinical utility.
    Santos JL, Ramos JA, Prieto P, Almoguera I, Vazquez C, Rubio ME, Cabranes JA.
    Prog Neuropsychopharmacol Biol Psychiatry; 1989 Aug; 13(6):917-25. PubMed ID: 2813809
    [Abstract] [Full Text] [Related]

  • 7. Haloperidol. Plasma levels and prolactin response as predictors of clinical improvement in schizophrenia: chemical v radioreceptor plasma level assays.
    Smith RC, Baumgartner R, Misra CH, Mauldin M, Shvartsburd A, Ho BT, DeJohn C.
    Arch Gen Psychiatry; 1984 Nov; 41(11):1044-9. PubMed ID: 6497566
    [Abstract] [Full Text] [Related]

  • 8. Haloperidol blood levels and effects in schizophrenia and schizoaffective disorder: a progress report.
    Volavka J, Cooper TB, Meisner M, Bitter I, Czobor P, Jaeger J.
    Psychopharmacol Bull; 1990 Nov; 26(1):13-7. PubMed ID: 2371368
    [Abstract] [Full Text] [Related]

  • 9. Haloperidol: therapeutic window in schizophrenia.
    Palao DJ, Arauxo A, Brunet M, Bernardo M, Haro JM, Ferrer J, Gonzalez-Monclus E.
    J Clin Psychopharmacol; 1994 Oct; 14(5):303-10. PubMed ID: 7806684
    [Abstract] [Full Text] [Related]

  • 10. Level of haloperidol in plasma is related to electroencephalographic findings in patients who improve.
    Czobor P, Volavka J.
    Psychiatry Res; 1992 May; 42(2):129-44. PubMed ID: 1631250
    [Abstract] [Full Text] [Related]

  • 11. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D, Thomas P, Leroux JM, Vaiga G, Pommery J, Cottencin O, Erb F, Goudemand M.
    Encephale; 1995 May; 21(6):417-24. PubMed ID: 8674466
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetic protocol for predicting plasma haloperidol concentrations.
    Miller DD, Perry PJ, Kelly MW, Coryell WH, Arndt SV.
    J Clin Psychopharmacol; 1990 Jun; 10(3):207-12. PubMed ID: 2376619
    [Abstract] [Full Text] [Related]

  • 13. Haloperidol and reduced haloperidol concentrations in plasma and red blood cells from chronic schizophrenic patients.
    Ko GN, Korpi ER, Kirch DG.
    J Clin Psychopharmacol; 1989 Jun; 9(3):186-90. PubMed ID: 2661607
    [Abstract] [Full Text] [Related]

  • 14. Correlates of rapid neuroleptic response in male patients with schizophrenia.
    Petrie EC, Faustman WO, Moses JA, Lombrozo L, Csernansky JG.
    Psychiatry Res; 1990 Aug; 33(2):171-7. PubMed ID: 2243894
    [Abstract] [Full Text] [Related]

  • 15. Plasma catecholamine metabolites in schizophrenics: evidence for the two-subtype concept.
    Chang WH, Chen TY, Lin SK, Lung FW, Lin WL, Hu WH, Yeh EK.
    Biol Psychiatry; 1990 Mar 01; 27(5):510-8. PubMed ID: 2310806
    [Abstract] [Full Text] [Related]

  • 16. Relationship of serum haloperidol levels to clinical response in schizophrenic patients.
    Magliozzi JR, Hollister LE, Arnold KV, Earle GM.
    Am J Psychiatry; 1981 Mar 01; 138(3):365-7. PubMed ID: 7468835
    [Abstract] [Full Text] [Related]

  • 17. Haloperidol plasma levels and clinical response: a therapeutic window relationship.
    Van Putten T, Marder SR, Mintz J, Poland RE.
    Am J Psychiatry; 1992 Apr 01; 149(4):500-5. PubMed ID: 1554036
    [Abstract] [Full Text] [Related]

  • 18. Haloperidol plasma levels and dose optimization.
    Coryell W, Miller DD, Perry PJ.
    Am J Psychiatry; 1998 Jan 01; 155(1):48-53. PubMed ID: 9433338
    [Abstract] [Full Text] [Related]

  • 19. Total and free plasma neuroleptic levels in schizophrenic patients.
    Tang SW, Glaister J, Davidson L, Toth R, Jeffries JJ, Seeman P.
    Psychiatry Res; 1984 Dec 01; 13(4):285-93. PubMed ID: 6596586
    [Abstract] [Full Text] [Related]

  • 20. Low plasma reduced haloperidol/haloperidol ratios in Chinese patients.
    Chang WH, Chen TY, Lee CF, Hu WH, Yeh EK.
    Biol Psychiatry; 1987 Nov 01; 22(11):1406-8. PubMed ID: 3663790
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.